Connect with us

Technology

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Published

on

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas.Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD, and double-digit royalties on annual salesAdditionally, Takeda will purchase a minority interest in Ascentage Pharma

ROCKVILLE, Md. and SUZHOU, China, June 14, 2024 /PRNewswire/ — Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today the signing of an option agreement with Takeda to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license exclusive global rights to develop and commercialize olverembatinib in all territories outside of among others, mainland China, Hong Kong, Macau, Taiwan, China.

Despite the impact TKIs have had in the treatment of patients with CML, there remains a significant unmet need for patients whose disease is resistant to these therapies or who develop hard-to-treat mutations following these treatments.

Under the terms of this option agreement, Ascentage Pharma is set to receive 100 million USD from Takeda to acquire the option to license olverembatinib. Ascentage will also be eligible for an option exercise fee and additional potential milestones of up to approximately 1.2 billion USD. Additionally, Ascentage Pharma is expected to receive a minority equity investment from Takeda.

As part of the agreement, Ascentage Pharma will continue to be solely responsible for all clinical development of olverembatinib before the potential exercise of the option to license olverembatinib. Olverembatinib is currently approved and marketed in China for the treatment of adult patients with TKI-resistant chronic-phase CML (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation, and in adult patients with CP-CML resistant to and/or intolerant of first-and second-generation TKIs.

“We are thrilled to enter into this agreement with Takeda, which would allow us to leverage the global commercial expertise of an organization with a proven track record and global oncology footprint to potentially broaden the impact olverembatinib could have on patients in need around the world,” said Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma. “Olverembatinib has already had a significant impact for patients with CML in China. We are excited to further the development of olverembatinib in our ongoing global registrational Phase 3 studies.”

“Throughout our history in oncology, Takeda has demonstrated a strong track record of working with companies that share our vision of bringing medicines to patients around the world with the highest unmet needs,” said Teresa Bitetti, president of Takeda’s Global Oncology Business Unit. “Through this agreement with Ascentage Pharma, we believe there is great potential to continue to advance this mission. We are highly encouraged by the promising results olverembatinib has shown in the clinic to date, and excited to have the opportunity to further develop and deliver it to patients with chronic myeloid leukemia and other hematological cancers.”

About Olverembatinib

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug has been included in the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Investors Contacts:IR@ascentage.com
Media Contacts:PR@ ascentage.com

Forward-Looking Statements

The forward-looking statements in this article relate only to the events or information as of the date on which the statements are made. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ascentage-pharma-signs-option-agreement-with-takeda-to-enter-into-exclusive-global-license-for-olverembatinib-a-third-generation-bcr-abl-tyrosine-kinase-inhibitor-tki-302173047.html

SOURCE Ascentage Pharma

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Driving Certainty Through Uncertainty: eclicktech’s Engineering Approach to Agentic AI

Published

on

By

XI’AN, China, May 9, 2026 /PRNewswire/ — As generative AI moves from experimentation to enterprise deployment, the industry focus is shifting from model capability to operational reliability. The challenge is no longer simply building smarter AI, but ensuring AI systems can operate safely and consistently inside complex production environments.

eclicktech recently shared its internal engineering practices around Agentic AI, highlighting how the company is applying context engineering, multi-cloud infrastructure, and layered security frameworks to support enterprise-scale AI deployment.

To support global operations across more than 230 countries and regions, eclicktech built its Cycor platform around a multi-cloud architecture integrating AWS, Google Cloud, Alibaba Cloud, Tencent Cloud, Huawei Cloud, and other providers. According to the company, this approach improves infrastructure flexibility, reduces vendor lock-in risk, and enables more efficient orchestration of large-scale Kubernetes clusters and AI workloads.

eclicktech stated that one of the key lessons from early Agent development was that prompt engineering alone was insufficient for enterprise deployment. The company therefore shifted toward context engineering — an approach focused on delivering the right information, at the right time, while optimizing limited token resources.

Its engineering framework includes six layers of context management covering active sessions, short-term memory, long-term semantic storage, knowledge graphs, operational experience, and reusable organizational skills. The system also supports proactive context injection, allowing relevant operational history and risk information to be surfaced automatically before sensitive actions are executed.

To improve inference efficiency, eclicktech introduced layered token governance and progressive tool-loading mechanisms, dynamically loading tools and information only when required. The company said this approach helped improve tool selection accuracy and reduce unnecessary token consumption during complex operational workflows.

Security remains a core requirement throughout the architecture. eclicktech’s governance framework includes namespace isolation, dry-run verification, human approval workflows, rule-based validation, and rollback mechanisms designed to reduce operational risks associated with AI-driven automation.

According to eclicktech, the next stage of enterprise AI competition will depend not only on model capability, but also on engineering reliability, infrastructure orchestration, context management, and organizational knowledge systems.

Note: Certain technical information referenced in this article is derived from eclicktech’s internal engineering practices and is provided for industry reference purposes only.

View original content:https://www.prnewswire.com/apac/news-releases/driving-certainty-through-uncertainty-eclicktechs-engineering-approach-to-agentic-ai-302767441.html

SOURCE eclicktech

Continue Reading

Technology

How a Unified Monetization Solution Is Driving eCPM and Revenue Growth for Casual Games Worldwide

Published

on

By

SINGAPORE, May 8, 2026 /PRNewswire/ — Casual, hyper-casual, and hybrid-casual games have become dominant categories in the global mobile market, making in-app advertising (IAA) a key driver of monetization success. However, many developers continue to face major challenges, including unstable fill rates, fluctuating eCPMs, difficulties balancing multiple regional markets, and the ongoing tradeoff between user experience and revenue growth.

To address these issues, zMaticoo has compiled a series of monetization case studies from leading game publishers and studios across China, Vietnam, Europe, and North America. These teams span hyper-casual, puzzle, board, card, and light-casual game categories, with DAUs ranging from millions to tens of millions. By adopting the same monetization framework, they achieved simultaneous growth in fill rate, eCPM, and ad revenue while maintaining stable user experience.

A common challenge among these teams was the shrinking monetization margin across global markets, creating an urgent need for sustainable revenue growth. At the same time, developers were cautious about over-monetization negatively impacting retention and player engagement.

To solve these challenges, zMaticoo introduced an AI-driven monetization system with full-funnel optimization capabilities. The platform connects developers directly to premium global advertiser budgets across both performance and brand advertising. AI models identify high-value traffic in real time based on region, audience, and usage scenarios, prioritizing high-eCPM demand sources. Separate bidding strategies are applied for mature and emerging markets to avoid revenue loss caused by one-size-fits-all pricing models.

The platform also provides refined ad format optimization:

Banner Ads: optimized display share and loading timing to improve SOV and stabilize eCPM;Interstitial Ads: precisely triggered during high-value moments such as level completion or pause screens, with especially strong premiums in emerging markets;Rewarded Video: deeply integrated into gameplay loops, delivering high user acceptance and conversion performance.

On the technical side, zMaticoo optimized SDK infrastructure to improve fill stability under weak network conditions. Ad loading time was reduced from five seconds to under two seconds through a rebuilt loading architecture. Progressive asset loading further minimized timeout-related drop-offs. AI-powered ad templates dynamically generated personalized creatives, improving both CTR and conversion performance.

The zMaticoo team also provides one-stop operational and analytics support. Developers can monitor fill rate, impressions, eCPM, and revenue through a unified dashboard, while dedicated optimization specialists provide 7×12 support for A/B testing, strategy iteration, and scaling guidance. The platform is deeply integrated with major mediation solutions, enabling one-time integration and multi-scenario deployment while reducing development and maintenance costs.

According to zMaticoo platform data:

In mature markets including the United States, Germany, Japan, and South Korea, banner eCPMs increased by 5%–10%, while interstitial premiums improved by over 5%;In emerging markets such as Brazil, Mexico, and Southeast Asia, interstitial eCPMs increased by more than 10%.

The monetization framework has demonstrated effectiveness across hyper-casual, puzzle, board/card, and utility app categories, supporting both rapid scale-up and long-term monetization stability.

Partner feedback includes:

“We are highly satisfied with the revenue uplift after integration. Our core products’ banner performance now ranks among the top tier.””Revenue recovered significantly after A/B testing, and we are expanding testing across more products.””One solution now supports multiple global markets without requiring separate monetization strategies for each region.””Interstitial monetization performance has been especially strong, with SOV reaching 10%–20% for several partners.”

zMaticoo believes successful monetization today is not about stacking more ad platforms, but about leveraging AI, technology, and refined operations to unlock long-term traffic value. Whether for hyper-casual publishers, puzzle game studios, or global mobile app companies, this AI-powered monetization framework is designed to deliver sustainable revenue growth while preserving user experience.

View original content:https://www.prnewswire.com/news-releases/how-a-unified-monetization-solution-is-driving-ecpm-and-revenue-growth-for-casual-games-worldwide-302767432.html

SOURCE zMaticoo

Continue Reading

Technology

Fox ESS Celebrates Strong Momentum with Integrated Solar Storage & Charging Solutions at Smart Energy 2026

Published

on

By

SYDNEY, May 9, 2026 /PRNewswire/ — Fox ESS, a global leader in renewable energy solutions, attended Smart Energy 2026 during 6-7 May as a platinum sponsor. At the event, Fox ESS showcased its next-generation approach to solar storage and EV charging solution, delivering a seamless, future-ready energy experience for homeowners and installers across Australia.

Integrated Solutions Tailored for Aussie Homes

At Smart Energy 2026, Fox ESS highlighted its storage-to-charging solution, designed to make everyday energy use more convenient for local residents. With performance-led products and proven market traction, Fox ESS is set to play its part in building a more resilient energy future for Australia.

Battery Systems

Fox ESS continues to build momentum in the battery market. Sunwiz, an Australian solar consultancy, recently reported that Fox ESS ranked No.1 in March for installation capacity. And the company also revealed it has installed more than 25,000 systems in April. During the exhibition, Sunwiz presented Fox ESS with an award, recognising the company as Top Solar Company for Fastest Growing Battery.

CQ7 V6+ High Voltage Battery (42kWh and above)
Building on Fox ESS’ proven strengths, compact design and high capacity, CQ7 V6+ is well suited to medium-sized households and ensure the free use of electricity and maximize the self-consumption.EQ4800 High Voltage Battery (28kWh)
A reliable choice for smaller households, designed for efficient day-to-day energy storage.

Alongside its battery range, Fox ESS showcased all-in-one systems, including Stackable AIO and EVO, designed to simplify installation while maintaining a high standard of design and presentation.

Inverters

Fox ESS offers a range of inverters to suit local requirements, supported by up to 200% PV oversizing and a 10-year product warranty.

Single-phase: H1‑G2 (3–6kW); KH series (7–10.5kW)Three-phase: H3 Smart (5–15kW); H3 Pro (15–29.9kW); H3 Plus (50–125kW)

EV Chargers

With EV adoption accelerating, Fox ESS also offers EV charging solutions with solar linkage, designed to work across its inverter portfolio. The chargers provide robust, smart energy management, including dynamic load balancing to help protect home circuits.

A Series (7.3kW / 11kW / 22kW): IP65 and IK08 protection, OCPP-compliant.L Series (7.3kW / 11kW): straightforward installation with multiple colour options.

Big Battery Still Takes Centre Stage

As the Cheaper Home Battery Program moves into a new phase under an updated rebate policy, interest in larger battery systems continues to grow, particularly as more households consider EV upgrades amid rising fuel costs. More EVs typically mean households need greater energy availability, making higher-capacity storage an increasingly attractive option.

Looking ahead, from 1 July 2026, the Australian Government’s Solar Sharer Offer (SSO) will provide eligible households with three hours of free daily electricity to align with peak solar generation. Households with larger batteries will be well placed to make the most of this opportunity.

Fox ESS is also working with local VPP partners, including Amber Electric and Origin Loop VPP, helping homeowners unlock maximum value while supporting greater grid stability.

Maimai Comes Alive at the Exhibition

Visitors to the Fox ESS stand experienced a full programme of brand activations across the event. Following the online announcement, Sydney served as Maimai’s first physical stop, bringing the community together for face-to-face engagement. Attendees queued to take photos with the brand’s friendly and recognisable mascot.

Long-Term Commitment to Australia

Fox ESS has opened two local offices in Melbourne and Sydney, with more than 30 dedicated specialists supporting local customer needs. The company is also looking to play a wider role in Australia’s energy transition.

Notably, Ian Thorpe made his first in-person appearance at Fox Night, where he presented partners with awards. At the event party, Fox ESS also hosted a battery installation challenge, featuring eight rounds of competition, with the final winners receiving a range of prizes.

“We’re delighted to see such a strong result following the rollout of local policy. With nearly 400,000 Australian households now installing batteries, Fox ESS has played a key role, but this is only the beginning. We’re committed to keeping momentum and helping make a smarter, more reliable energy future a reality for more homes.” said Brooks Richard Geng, APAC & Middle East Managing Director, Fox ESS.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/fox-ess-celebrates-strong-momentum-with-integrated-solar-storage–charging-solutions-at-smart-energy-2026-302767429.html

SOURCE Fox ESS

Continue Reading

Trending